Logo image
Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine
Journal article   Peer reviewed

Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine

Barbara A Cromer, Delia Scholes, Abbey Berenson, Tim Cundy, M Kathleen Clark and Andrew M Kaunitz
The Journal of adolescent health : official publication of the Society for Adolescent Medicine, Vol.39(2), pp.296-301
08/2006
DOI: 10.1016/j.jadohealth.2006.03.011
PMID: 16857545

View Online

Abstract

The purpose of this Position Paper is to review the published Black Box Warning regarding depot medroxyprogesterone acetate (DMPA) and bone loss as it relates to adolescent girls. The scientific findings that prompted the Food and Drug Administration to issue the warning are reviewed and the following additional issues are considered: (1) likely low risk of fracture related to DMPA use, (2) evidence of at least partial recovery after discontinuation of the method, and (3) the need to balance the physical, social and economic cost of adolescent pregnancy versus the immediate and long-term impact of DMPA on bone. A list of clinical guidelines is included, the main recommendation of which is to continue prescription of DMPA, with counseling about the risks and benefits, in most of the adolescent population desiring to use this contraceptive method.
United States Counseling Contraceptive Agents, Female - adverse effects Calcium, Dietary Humans Contraceptive Agents, Female - administration & dosage Adolescent Medicine Contraindications Bone Density - drug effects Drug Labeling Fractures, Bone - etiology Societies, Medical Adolescent Medroxyprogesterone Acetate - adverse effects Female Bone Resorption - chemically induced Medroxyprogesterone Acetate - administration & dosage Delayed-Action Preparations United States Food and Drug Administration

Details

Logo image